After filing high-stakes lawsuits against countries that stopped buying its vaccines, Pfizer is making a big push into diet pills

Pfizer said it will continue to develop a once-daily version of its weight-loss drug danuglipron after seeing “encouraging” data in an early study. The company plans to conduct further studies in the second half of the year. The pharmaceutical giant halted trials of twice-daily danuglipron in December because patients had difficulty tolerating the drug.

On Thursday, Pfizer said it would move forward with the launch of its once-daily weight-loss drug danuglipron after seeing “encouraging” data in an early study. Pfizer said it plans to conduct more early-stage studies in the second half of this year to determine the ideal dose for the drug. Results will be available in the first quarter of next year, a spokesperson told CNBC. Pfizer is one of several drugmakers vying for market share in a very popular class of weight-loss and diabetes drugs.

Copy URL
URL copied